​

Xeris Biopharma (XERS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

XERS Stock Forecast

Xeris Biopharma (XERS) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $13.50, with a high of $18.00 and a low of $9.00. This represents a 80.48% increase from the last price of $7.48.

- $4 $8 $12 $16 $20 High: $18 Avg: $13.5 Low: $9 Last Closed Price: $7.48

XERS Stock Rating

Xeris Biopharma stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

XERS Price Target Upside V Benchmarks

TypeNameUpside
StockXeris Biopharma80.48%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-23
Avg Price Target-$13.50$10.33
Last Closing Price$7.48$7.48$7.48
Upside/Downside-80.48%38.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26151--7
Dec, 25-41--5
Nov, 25141--6
Oct, 25141--6
Sep, 25141--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 08, 2025Barclays$9.00$6.9928.76%20.32%
Oct 29, 2025Leland GershellOppenheimer$18.00$9.9780.54%140.64%
Mar 07, 2025Piper Sandler$4.00$4.24-5.66%-46.52%
Nov 11, 2024Oren LivnatH.C. Wainwright$6.60$3.25103.08%-11.76%
Oct 23, 2024Leland GershellOppenheimer$5.00$3.0265.56%-33.16%
May 10, 2024David AmsellemPiper Sandler$3.00$1.8562.16%-59.89%
Apr 28, 2022Craig-Hallum$6.50$2.33178.97%-13.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 31, 2025JefferiesBuyBuyhold
Dec 08, 2025BarclaysOverweightinitialise
Oct 29, 2025OppenheimerOutperformOutperformhold
Mar 07, 2025Craig-HallumBuyBuyhold
Mar 07, 2025Piper SandlerNeutralNeutralhold
Mar 07, 2025H.C. WainwrightBuyBuyhold
Nov 11, 2024H.C. WainwrightBuyBuyhold
Nov 11, 2024Piper SandlerOverweightNeutraldowngrade
Oct 23, 2024OppenheimerOutperformOutperformhold
Aug 09, 2024Craig-HallumBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.20$-0.70$-0.45------
Avg Forecast$-1.22$-0.42$-0.39$-0.22$-0.03$0.18$0.37$0.64$0.81
High Forecast$-1.12$-0.36$-0.36$-0.05$0.02$0.31$0.67$0.74$0.93
Low Forecast$-1.28$-0.48$-0.43$-0.30$-0.05$0.05$0.12$0.59$0.74
Surprise %-1.64%66.67%15.38%------

Revenue Forecast

$0 $130M $260M $390M $520M $650M Dec 21 Dec 22 Dec 23 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$110.25M$110.25M$163.91M------
Avg Forecast$47.47M$165.00M$162.58M$239.25M$287.42M$367.52M$435.30M$496.38M$571.10M
High Forecast$49.26M$179.31M$163.59M$260.00M$288.57M$424.98M$487.94M$556.40M$640.16M
Low Forecast$44.47M$150.41M$161.88M$218.10M$284.97M$332.18M$406.53M$463.57M$533.36M
Surprise %132.25%-33.18%0.82%------

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 21 Dec 22 Dec 23 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-94.66M$-94.66M$-62.26M------
Avg Forecast$-167.69M$-57.82M$-54.18M$-30.29M$-6.11M$28.60M$61.09M$94.01M$118.15M
High Forecast$-153.90M$-49.56M$-49.61M$-6.88M$2.65M$45.22M$98.17M$108.79M$136.73M
Low Forecast$-175.91M$-66.08M$-58.75M$-41.30M$-7.95M$7.72M$17.70M$85.94M$108.00M
Surprise %-43.55%63.71%14.91%------

XERS Forecast FAQ

Is Xeris Biopharma stock a buy?

Xeris Biopharma stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Xeris Biopharma is a favorable investment for most analysts.

What is Xeris Biopharma's price target?

Xeris Biopharma's price target, set by 10 Wall Street analysts, averages $13.5 over the next 12 months. The price target range spans from $9 at the low end to $18 at the high end, suggesting a potential 80.48% change from the previous closing price of $7.48.

How does Xeris Biopharma stock forecast compare to its benchmarks?

Xeris Biopharma's stock forecast shows a 80.48% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Xeris Biopharma over the past three months?

  • January 2026: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Xeris Biopharma’s EPS forecast?

Xeris Biopharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.22, marking a -51.11% decrease from the reported $-0.45 in 2023. Estimates for the following years are $-0.03 in 2025, $0.18 in 2026, $0.37 in 2027, $0.64 in 2028, and $0.81 in 2029.

What is Xeris Biopharma’s revenue forecast?

Xeris Biopharma's average annual revenue forecast for its fiscal year ending in December 2024 is $239.25M, reflecting a 45.96% increase from the reported $163.91M in 2023. The forecast for 2025 is $287.42M, followed by $367.52M for 2026, $435.3M for 2027, $496.38M for 2028, and $571.1M for 2029.

What is Xeris Biopharma’s net income forecast?

Xeris Biopharma's net income forecast for the fiscal year ending in December 2024 stands at $-30.288M, representing a -51.35% decrease from the reported $-62.255M in 2023. Projections indicate $-6.115M in 2025, $28.6M in 2026, $61.09M in 2027, $94.01M in 2028, and $118.15M in 2029.